ストックスクリーナーアプリを入手
138.80
0.95%
-1.33
プレマーケット:
140.99
2.19
+1.58%
前日終値:
$140.13
開ける：
$139
24時間の取引高:
5.42M
Relative Volume:
0.77
時価総額：
$172.28B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
20.47
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
-0.41%
1か月 パフォーマンス:
-3.56%
6か月 パフォーマンス:
+18.86%
1年 パフォーマンス:
+31.54%
1日の値動き範囲:
$137.15
$139.39
1週間の範囲:
$137.15
$141.49
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
138.80 | 172.28B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
931.09 | 831.80B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.41 | 574.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.37 | 365.02B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.81 | 311.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.28 | 294.91B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences Is Doubling Down On Acquisitions (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating - TipRanks
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $174 - moomoo.com
Oppenheimer reiterates Gilead stock rating on acquisition strategy - Investing.com
Gilead strengthens ADC capabilities with $5bn Tubulis acquisition - European Pharmaceutical Review
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewswire Inc.
Gilead Tubulis Deal Expands ADC Oncology Pipeline And Valuation Debate - simplywall.st
With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger' - Fierce Biotech
Gilead's Stock Price is Expected to Rise to $160，Gilead’s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America - TradingKey
Is Gilead Sciences (GILD) Among the Best Low Volatility Blue Chip Stocks to Buy Now? - Yahoo Finance
Gilead Sciences Expands Pipeline with Tubulis, Ouro, and Arcellx Deals - National Today
Gilead to Acquire Tubulis for Up to $5 Billion to Expand Cancer Drug Pipeline - Barchart
Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom - Yahoo Finance
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline ExpansionSlideshow (NASDAQ:GILD) 2026-04-07 - Seeking Alpha
Gilead buying Tubulis and its ADCs in $5B takeover bid - BioWorld MedTech
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline - Reuters
Gilead’s $3.15 Billion Tubulis Grab Puts Cambridge Outpost In The Spotlight - Hoodline
Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why - Stocktwits
Gilead Sciences Is Betting on a Bavarian Biotech For Its Comeback - Yahoo Finance
Gilead to buy cancer biotech Tubulis for more than $3 billion - statnews.com
Gilead to Acquire Tubulis, Expanding Antibody-Drug Conjugate Portfolio - National Today
Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History - ca.finance.yahoo.com
Gilead’s 2026 Shopping Spree Continues With Tubulis Buyout - Citeline News & Insights
Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis - MedCity News
American biopharmaceutical company Gilead acquires German Tubulis for $5 billion - AKM.RU
Gilead (GILD) to Acquire Tubulis, Strengthening Antibody-Drug Co - GuruFocus
Gilead (GILD) to Acquire Tubulis in $5 Billion Deal - GuruFocus
Gilead to buy Germany’s Tubulis for up to US$5 billion to boost cancer pipeline - BNN Bloomberg
Gilead Sciences Acquires Tubulis for $3 Billion - National Today
Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities - Genetic Engineering and Biotechnology News
Gilead's deal spree rolls on with Tubulis takeover for up to $5B - FirstWord Pharma
Gilead to Buy Cancer Biotech Tubulis in $5 Billion Deal - Bloomberg.com
Gilead Sciences, Inc. entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion. - marketscreener.com
Gilead Sciences to acquire Tubulis for up to $5 billion - VC Magazin
Cambridge biotech bought by Gilead for $3.15B - The Business Journals
Gilead to Buy German Biotech Tubulis for Up to $5 Billion. The Stock Falls. - Barron's
Gilead Acquisition Spree Continues With $3 Billion Tubulis DealGilead Sciences (NASDAQ:GILD) - Benzinga
5 Firms Advise On Gilead's Up To $5B Tubulis Acquisition - Law360
Gilead expands antibody conjugate capabilities with $5bn Tubulis buy - BioXconomy
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis - BioPharma Dive
Andera Partners-backed Tubulis from Munich snapped up by Gilead Sciences in multi-billion dollar ADC deal - European Biotechnology Magazine
Gilead goes big with $5 billion Tubulis buy - thepharmaletter.com
US pharma firm Gilead to acquire German biotech company Tubulis to boost cancer pipeline - Anadolu Ajansı
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis - BioSpace
Gilead to acquire Tubulis for $3.15 billion upfront - Investing.com
EQS-News: Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline.boerse.de - boerse.de
Press Release: EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for up to USD 5.0 Billion - moomoo.com
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update - marketscreener.com
Gilead to buy Tubulis to help cancer drug pipeline - Business Day
Gilead to Buy German Biotech Tubulis for $3 Billion for Experimental Cancer Drugs - WSJ
Gilead strikes again, penning $5bn deal to buy Tubulis - pharmaphorum
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
0.75%
大文字化:
|
ボリューム (24 時間):